Epilepsy

Fycompa Approved for Younger Epilepsy Patients With Partial-Onset Seizures

Fycompa Approved for Younger Epilepsy Patients With Partial-Onset Seizures

By

Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing.

DEA Reschedules Marijuana-Based Drug Epidiolex

DEA Reschedules Marijuana-Based Drug Epidiolex

By

Drugs with a Schedule V classification have proven medical use and low abuse potential.

NDA Submitted for Valtoco Nasal Spray to Treat Acute Repetitive Seizures

NDA Submitted for Valtoco Nasal Spray to Treat Acute Repetitive Seizures

By

The Company states that the NDA is supported by robust clinical trial data, including patients studies where more than 1600 seizures were treated with Valtoco nasal spray.

Folic Acid Supplementation May Protect Against Language Delay in AED-Exposed Children

Folic Acid Supplementation May Protect Against Language Delay in AED-Exposed Children

By

The odds of language delay were lower at 18 months and 36 months in children exposed to AEDs in utero whose mothers took folic acid.

Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist

Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist

By

This widespread variation in strategies may contribute to undesirable outcomes that are characterized by poor seizure control and added deficits.

Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies

Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies

By

Although 2 patients experienced an increase in seizure frequency, the remaining patients did not experience a change in frequency.

Add-On Cannabidiol Reduces Seizure Frequency in Treatment-Refractory Epilepsy

Add-On Cannabidiol Reduces Seizure Frequency in Treatment-Refractory Epilepsy

By

Countable seizure types were recorded in parents' and caregivers' clinical diaries during a 4-week baseline period.

Clinical Factors Influencing Neuroimaging Yield in Nonindex Seizures Identified

Clinical Factors Influencing Neuroimaging Yield in Nonindex Seizures Identified

By

The investigators sought to detect whether neuroimaging during an emergency department visit was associated with acute changes in the management of patients.

Late-Onset Epilepsy Linked to <i>APOE</i> ε4, Smoking, Diabetes

Late-Onset Epilepsy Linked to APOE ε4, Smoking, Diabetes

By

The risk for late-onset epilepsy was lower in patients with higher physical activity levels and moderate alcohol intake.

Outcomes After Seizure Recurrence Upon AED Withdrawal Following Temporal Lobectomy

Outcomes After Seizure Recurrence Upon AED Withdrawal Following Temporal Lobectomy

By

Recurrence of seizures was reported in 28.2% of patients who attempted withdrawal.

Sympazan Oral Film Granted Tentative Approval for Lennox-Gastaut Syndrome

Sympazan Oral Film Granted Tentative Approval for Lennox-Gastaut Syndrome

By

Clobazam is currently available as oral tablets and suspension under the trade name Onfi (Lundbeck).

Everolimus, Sirolimus Generally Safe for Epilepsy in Tuberous Sclerosis Complex

Everolimus, Sirolimus Generally Safe for Epilepsy in Tuberous Sclerosis Complex

By

Approximately 78% of treated patients experienced at least 1 treatment-related adverse event.

Anticonvulsants Not Associated With Risk for Perinatal Bleeding

Anticonvulsants Not Associated With Risk for Perinatal Bleeding

By

The findings offer some reassurance for clinicians and for pregnant women who are successfully treated with enzyme-inducing ACDs.

Diacomit Approved for the Treatment of Dravet Sydrome

Diacomit Approved for the Treatment of Dravet Sydrome

By

Diacomit was evaluated in 2 multicenter, placebo-controlled, double-blind, randomized studies.

Early Treatment Failure More Likely With Carbamazepine vs Lamotrigine in Epilepsy

Early Treatment Failure More Likely With Carbamazepine vs Lamotrigine in Epilepsy

By

The results of this review are applicable primarily to persons with focal onset seizures, with 88% of included participants experiencing this type of seizure at baseline.

High Anxiety Symptoms Prevalent in Epilepsy, Mesial Temporal Sclerosis

High Anxiety Symptoms Prevalent in Epilepsy, Mesial Temporal Sclerosis

By

Investigators assessed demographic and epilepsy-specific factors independently associated with anxiety, including lesions and seizure focus localization.

Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines

Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines

By

An expert subcommittee was formed consisting of members of the AAN and AES to update the 2004 evidence-based guidelines on epilepsy treatment with AEDs.

Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits

Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits

By

Studies that have evaluated the use of VNS in children, including those as young as 6 months old, and have generally concluded that it is well tolerated and improves quality of life.

Viral vector based gene therapies show promise for treating focal epilepsy [PreClinical]

Seizures are often associated with accumulation of extracellular glutamate due to the synchronous discharges of excitatory neurons.

New Formulation of Status Epilepticus Treatment To Be Reviewed

New Formulation of Status Epilepticus Treatment To Be Reviewed

By

The NDA for IM/IV Captisol-Enabled Fosphenytoin has been accepted for review and given a Prescription Drug Fee User Act date, by the FDA.

Modifiable Midlife Risk Factors Linked to Late-Onset Epilepsy

Modifiable Midlife Risk Factors Linked to Late-Onset Epilepsy

Potentially modifiable risk factors in midlife are associated with the risk of developing late-onset epilepsy.

Addressing Psychiatric Comorbidities in Pediatric Epilepsy: Expert Opinions

Addressing Psychiatric Comorbidities in Pediatric Epilepsy: Expert Opinions

By

Cognitive and linguistic deficits have been cited as risk factors for psychiatric comorbidity in pediatric epilepsy, along with family factors such as parenting style and quality of the parent-child relationship.

Disease-Specific ICD Code Helps Identify Infantile Spasms in Claims Data

Disease-Specific ICD Code Helps Identify Infantile Spasms in Claims Data

By

Claims data spanning 4 years were obtained from a pediatric accountable care organization.

Evidence for Clobazam Monotherapy Use in Focal, Generalized Seizures Reviewed

Evidence for Clobazam Monotherapy Use in Focal, Generalized Seizures Reviewed

By

The safety and efficacy of clobazam monotherapy in patients with new-onset focal or generalized seizures was investigated in a new Cochrane systematic review.

Weight-Adjusted Lacosamide Effective for Benzodiazepine-Resistant Status Epilepticus

Weight-Adjusted Lacosamide Effective for Benzodiazepine-Resistant Status Epilepticus

By

The efficacy was reported to be significantly higher in patients who had taken benzodiazepines.

Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths

Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths

By

Causes of death in patients with epilepsy were assessed to determine the presence of cardiac pathology.

Vigadrone Available for Refractory Complex Partial Seizures, Infantile Spasms

Vigadrone Available for Refractory Complex Partial Seizures, Infantile Spasms

By

The FDA has approved an abbreviated New Drug Application for Vigadrone, the generic alternative to Sabril powder for oral solution.

Significant Changes in Serotonin Levels Observed Following Epileptic Seizures

Significant Changes in Serotonin Levels Observed Following Epileptic Seizures

By

Investigators sought to examine whether seizures are capable of causing changes in serotonin levels in the peripheral circulation.

Next-Generation Sequencing May Improve Pediatric Epilepsy Tx

Next-Generation Sequencing May Improve Pediatric Epilepsy Tx

Next-generation sequencing can improve treatment efficacy and reduce hospitalization in children with drug-resistant epilepsy.

First Marijuana-Based Drug Approved to Treat LGS, Dravet Syndrome

First Marijuana-Based Drug Approved to Treat LGS, Dravet Syndrome

By

This marks the first approved drug that contains an active ingredient derived from marijuana as well as the first treatment approved for patients with Dravet syndrome.

Sign Up for Free e-newsletters



CME Focus